ArticleEJNMMI research2012
Emerging role of radiolabeled nanoparticles as an effective diagnostic technique.
Article in EJNMMI research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 145 citations in OpenAlex.
- Fructose-Based Single-Chain Polymer Nanoparticles for GLUT1-Mediated Delivery: Impact of Polymer Design on Uptake and In Vivo Performance.Advanced healthcare materials · 2026Article
- Advances in nanotechnology for early cancer diagnosis: emerging nanoplatforms and multimodal imaging approaches.American journal of cancer research · 2026Review
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Mannosamine-Modified Poly(lactic-Bioconjugate chemistry · 2025Article
- Advances in Ultrasmall Inorganic Nanoparticles for Nanomedicine: From Diagnosis to Therapeutics.ACS applied materials & interfaces · 2025Review
- Conventional and microfluidic methods: Design and optimization of lipid-polymeric hybrid nanoparticles for gene therapy.Drug delivery and translational research · 2025Article
- Article
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- From bone to nanoparticles: development of a novel generation of bone derived nanoparticles for image guided orthopedic regeneration.Biomaterials science · 2024Article
- Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm.Chemical & biomedical imaging · 2024Review
- Gamma-Camera Direct Imaging of the Plasma and On/Intra Cellular Distribution of theMaterials (Basel, Switzerland) · 2024Article
- Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI.Nanomaterials (Basel, Switzerland) · 2023Review
- Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations.Journal of nanobiotechnology · 2022Review
- Single-Step Self-Assembly of Zein-Honey-Chitosan Nanoparticles for Hydrophilic Drug Incorporation by Flash Nanoprecipitation.Pharmaceutics · 2022Article
- Nanomicelles of Radium Dichloride [Polymers · 2022Article
- Nanomaterial Probes for Nuclear Imaging.Nanomaterials (Basel, Switzerland) · 2022Review
- Long-Circulation and Brain Targeted Isoliquiritigenin Micelle Nanoparticles: Formation, Characterization, Tissue Distribution, Pharmacokinetics and Effects for Ischemic Stroke.International journal of nanomedicine · 2022Article
- Fully Natural Lecithin Encapsulated Nano-Resveratrol for Anti-Cancer Therapy.International journal of nanomedicine · 2022Article
- Recent progress in micro and nano-encapsulation of bioactive derivatives of the Brazilian genus Pterodon.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation timeAsian journal of pharmaceutical sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicine is emerging as a promising approach for diagnostic applications. Nanoparticles are structures in the nanometer size range, which can present different shapes, compositions, charges, surface modifications, in vitro and in vivo stabilities, and in vivo performances. Nanoparticles can be made of materials of diverse chemical nature, the most common being metals, metal oxides, silicates, polymers, carbon, lipids, and biomolecules. Nanoparticles exist in various morphologies, such as spheres, cylinders, platelets, and tubes. Radiolabeled nanoparticles represent a new class of agent with great potential for clinical applications. This is partly due to their long blood circulation time and plasma stability. In addition, because of the high sensitivity of imaging with radiolabeled compounds, their use has promise of achieving accurate and early diagnosis. This review article focuses on the application of radiolabeled nanoparticles in detecting diseases such as cancer and cardiovascular diseases and also presents an overview about the formulation, stability, and biological properties of the nanoparticles used for diagnostic purposes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.